Income in the year 2019 increased generally; emphasis should be placed on the increase in international grants for the neurosciences programme and the inflammation programme (among others, the Alzheimer Association, WADA and the Cancer Research Institute) and from the European Union for the bioinformatics and inflammations programme, as well as grants from the Carlos III Institute for the neurosciences and inflammation programme. In contrast the grants awarded under the PERIS (Health Research and Innovation Strategic Plan) have suffered a decline.

With respect to other income, it is important to highlight the increase in invoiced revenue from clinical trials (mainly in the cancer programme) and services contracts (mainly in the neurosciences and inflammation programmes).

External funding

​

 

Sources of funding

​

 

Profit and loss account

​

 

Assets

​